Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | DAO | P14920 | 2/20 | 0.31 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.30 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | DDO | Q99489 | 1/20 | 0.30 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL558333 | 0.67 | FFAR1 (0.32) | GPR84DAODDOSLC6A4 | |
| SCHEMBL2557 | 0.66 | — | — | |
| SCHEMBL1969683 | 0.64 | CA12 (0.38) | CA12CA9GPR84DAODDO | |
| SCHEMBL2071956 | 0.61 | CA12 (0.36) | CA12CA9GPR84DAODDO | |
| SCHEMBL11903870 | 0.61 | GPR84 (0.39) | CA12CA9GPR84MAPK10RIPK1 | |
| SCHEMBL16178984 | 0.60 | PARP1 (0.35) | CA12CA9GPR84DAOMAPK10 | |
| SCHEMBL160264 | 0.60 | — | — | |
| SCHEMBL3519434 | 0.60 | NOS1 (0.59) | CA12CA9DAOMAPK10RIPK1 | |
| SCHEMBL207457 | 0.60 | METAP2 (0.38) | GPR84DAOMPO | |
| SCHEMBL786302 | 0.58 | CHEK1 (0.60) | GPR84MAPK10RIPK1MPOSLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2680844-A2 | AMINO-QUINOLINES AS KINASE INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2014-01-08 | — | — | EP | claimed |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2013-01-24 | — | — | US | claimed |
| WO-2012122011-A2 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | claimed |
| JP-4808156-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1663994-A1 | CONDENSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | claimed |
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-25 | — | — | US | claimed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | claimed |
| CN-117440774-A | Biomarkers of age-related macular degeneration | 倍亮生物有限责任公司 | 2024-01-23 | — | — | CN | disclosed |
| CN-114364382-A | Formulations and methods of use of RBP4 inhibitors | 倍亮生物有限责任公司 | 2022-04-15 | — | — | CN | disclosed |
| US-10220030-B2 | Amino-quinolines as kinase inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2019-03-05 | — | — | US | disclosed |
| US-20180085365-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| WO-2017133667-A1 | PYRIMIDINE AND PYRIDINE DERIVATIVES AND USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA THEREOF | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| WO-2017133670-A1 | PYRIDINE AND PYRIMIDINE DERIVATIVES AND THEIR USE IN TREATMENT, AMELIORATION OR PREVENTION OF INFLUENZA | SAVIRA PHARMACEUTICALS GMBH (AT) | 2017-08-10 | — | — | WO | disclosed |
| WO-2012122011-A2 | AMINO-QUINOLINES AS KINASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-09-13 | — | — | WO | disclosed |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS, INC. (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011120025-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2011-09-29 | — | — | WO | disclosed |
| US-7968545-B2 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INC. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1663994-A1 | CONDENSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | Vertex Pharmaceuticals Incorporated (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2005-08-25 | — | — | US | disclosed |
| WO-2005014558-A1 | CONDENSED PYRAMIDINE COMPOUNDS AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187217-A1 | Compositions useful as inhibitors of voltage-gated ion channels | KCNQ1, KCNN2, KCNH3 | CA12 2678/4885CA9 2258/4885GPR84 2603/4885 |
| US-10220030-B2 | Amino-quinolines as kinase inhibitors | ABL1, MAP3K3, MAP3K7 | CA12 4821/4885CA9 4607/4885GPR84 1766/4885 |
| US-20120040935-A1 | COMPOSITIONS USEFUL AS INHIBITORS OF VOLTAGE-GATED ION CHANNELS | KCNQ1, KCNN2, KCNH3 | CA12 2678/4885CA9 2258/4885GPR84 2603/4885 |
| US-20180085365-A1 | AMINO-QUINOLINES AS KINASE INHIBITORS | ABL1, MAP3K3, MAP3K7 | CA12 4821/4885CA9 4607/4885GPR84 1766/4885 |
| US-20130023532-A1 | INDAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | MAP3K19, MAP3K1, MAP3K20 | CA12 4839/4885CA9 3783/4885GPR84 2873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.